Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the ...

In this strange new world where a weekly injection can quickly achieve what years of attempted diets may fail to do, the ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Novo Nordisk, the Danish pharma heavyweight behind Ozempic, is feeling the squeeze as its once-booming diabetes drug sales ...

Novo Nordisk faces a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to intense competition ...

Influencer Tana Mongeau has warned against taking the weight loss drug Mounjaro after she experienced severe side effects.

Novo Nordisk is facing a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to increased competition and potential US tariffs.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

The amount of credits the company receives is contingent upon its meeting job creation and capital investment goals.

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your appetite. Yep, they’ve realised waving a patient goodbye into the sunset ...